IDEXX Laboratories, Inc. $IDXX Shares Acquired by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 419.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 95,890 shares of the company’s stock after purchasing an additional 77,438 shares during the quarter. AustralianSuper Pty Ltd’s holdings in IDEXX Laboratories were worth $61,263,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Blalock Williams LLC purchased a new position in IDEXX Laboratories in the third quarter valued at about $590,000. Arkadios Wealth Advisors acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at about $405,000. Orion Porfolio Solutions LLC raised its holdings in shares of IDEXX Laboratories by 116.6% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock valued at $5,749,000 after buying an additional 5,770 shares during the period. USA Financial Formulas purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $2,381,000. Finally, Beacon Investment Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 15.7% in the 3rd quarter. Beacon Investment Advisory Services Inc. now owns 56,241 shares of the company’s stock worth $35,932,000 after acquiring an additional 7,616 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 1.0%

NASDAQ:IDXX opened at $687.74 on Thursday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. The company has a market capitalization of $54.92 billion, a price-to-earnings ratio of 54.54, a price-to-earnings-growth ratio of 3.72 and a beta of 1.67. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The stock has a 50-day simple moving average of $706.71 and a 200 day simple moving average of $658.79.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.98% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. BTIG Research raised their price target on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, January 12th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Barclays started coverage on IDEXX Laboratories in a research note on Monday, December 8th. They set an “overweight” rating and a $850.00 target price for the company. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.